GGrantIndex
← Leaderboards

Shiva Shahrara

Northwestern University

$3,709,581
Attributed
$4,225,927
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $714.8K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,225,927 · 6
VA$0 · 3

By mechanism

R01$2,137,878 · 1
R41$600,000 · 1
K01$587,535 · 1
R03$467,821 · 2
R43$432,693 · 1
IK6$0 · 1

Top collaborators

Others in their field

Top investigators on “Rheumatoid Arthritis

Research focus

Rheumatoid ArthritisCellsMacrophageJointsLigandsInflammatoryArthritisSynovial FluidLigationTissuesAutoimmune DiseasesBone ErosionMediatingPathway InteractionsPlayMyeloid CellsMonocyteTnf GeneLinkChronicInterleukin-6T-LymphocyteAffectBinding

Grant awards (29)

Identifying a novel pathway that regulates RA immunometabolism$714,758
R01 · FY2025 · AI · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Establishing novel therapeutic strategies to target RA pannus formation$0
I01 · FY2024 · VA · contact PI
Identifying a novel pathway that regulates RA immunometabolism$714,758
R01 · FY2023 · AI · contact PI
Discovering a novel therapy for RA patients$0
I01 · FY2023 · VA · contact PI
Identifying a novel pathway that regulates RA immunometabolism$708,362
R01 · FY2022 · AI · contact PI
Discovering a novel therapy for RA patients$0
I01 · FY2022 · VA · contact PI
Engineering a unique antibody for patients with RA$300,000
R41 · FY2021 · AI
Discovering a novel therapy for RA patients$0
I01 · FY2021 · VA · contact PI
Engineering a unique antibody for patients with RA$300,000
R41 · FY2020 · AI
Discovering a novel therapy for RA patients$0
I01 · FY2020 · VA · contact PI
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$208,072
R43 · FY2018 · AG
Ligation of TLR7 promotes joint inflammation and bone loss in RA.$0
I01 · FY2018 · VA · contact PI
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$224,621
R43 · FY2017 · AG
Ligation of TLR7 promotes joint inflammation and bone loss in RA.$0
I01 · FY2017 · VA · contact PI
Identifying a novel link between two potent proangiogenic cascades in RA$79,750
R03 · FY2016 · AR · contact PI
Ligation of TLR7 promotes joint inflammation and bone loss in RA.$0
I01 · FY2016 · VA · contact PI
Identifying a novel link between two potent proangiogenic cascades in RA$79,750
R03 · FY2015 · AR · contact PI
Ligation of TLR7 promotes joint inflammation and bone loss in RA.$0
I01 · FY2015 · VA · contact PI
Identifying a novel link between two potent proangiogenic cascades in RA$79,750
R03 · FY2014 · AR · contact PI
The Role of IL-17 in Monocyte Migration$74,606
R03 · FY2011 · AR · contact PI
The Role of IL-17 in Monocyte Migration$77,715
R03 · FY2010 · AR · contact PI
The Role of IL-17 in Monocyte Migration$76,250
R03 · FY2009 · AR · contact PI
Chemokine receptor antagonists in inflammatory disease$117,507
K01 · FY2007 · AR · contact PI
Chemokine receptor antagonists in inflammatory disease$117,507
K01 · FY2006 · AR · contact PI
Chemokine receptor antagonists in inflammatory disease$117,507
K01 · FY2005 · AR
Chemokine receptor antagonists in inflammatory disease$117,507
K01 · FY2004 · AR
Chemokine receptor antagonists in inflammatory disease$117,507
K01 · FY2003 · AR